CBIO
Crescent Biopharma, Inc.
There isn't enough reported data to score CBIO yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
CBIO Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
CBIO's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
CBIO PE Valuation
CBIO has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
CBIO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect CBIO's losses to shrink, with revenue declining.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
CBIO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2025 | -$17.88 | +$44.12 |
| Q2 2025 | -$31.37 | +$29.63 |
| Q1 2025 | -$46.00 | +$12.00 |
| Q4 2024 | -$59.00 | -$1.00 |
| Q3 2024 | -$62.00 | +$2.00 |
| Q2 2024 | -$61.00 | +$5.00 |
| Q1 2024 | -$58.00 | +$20.00 |
| Q4 2023 | -$58.00 | +$31.00 |
CBIO has the stronger earnings trend. Trailing diluted EPS is down 129% for CBIO versus HIMS down 257%.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
CBIO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2022 | $75K | +52717% |
| Q4 2021 | $17.6K | -89% |
| Q3 2021 | $86.6K | -91% |
| Q1 2021 | $1.1M | -88% |
CBIO's revenue is growing: $3M last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1280% | N/A |
| Q1 2026 | -2380% | N/A |
| Q2 2022 | -17804% | +10126197 points |
| Q4 2021 | -98870% | -89315 points |
| Q3 2021 | -20029% | -18656 points |
| Q2 2021 | -10144001% | N/A |
| Q1 2021 | -1353% | -1263 points |
| Q4 2020 | -9555% | N/A |
CBIO's operating margin was −1280% last quarter, up 18749 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over CBIO on profitability, with a higher operating margin.
CBIO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$26.9M | -$8.8M |
| Q4 2025 | -$26.9M | -$23.2M |
| Q3 2025 | -$18.1M | -$10.1M |
| Q4 2024 | -$3.7M | +$3.9M |
| Q3 2024 | -$8M | +$696.7K |
| Q2 2024 | -$8.9M | -$1.9M |
| Q1 2024 | -$10.5M | +$1.1M |
| Q4 2023 | -$7.6M | +$295.8K |
CBIO has burned cash in almost every quarter: −$82M over the past year, against −$39M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over CBIO on cash generation, producing positive trailing cash flow while its opponent burns cash.
CBIO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.7% | +1.8M shares |
| 1 year | +180% | +25M shares |
| 3 years | +5944% | +38.3M shares |
| 5 years | +7443% | +38.4M shares |
| Available history | +8892% | +38.5M shares |
CBIO has 39M diluted shares, up 180% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over CBIO on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
CBIO Net Leverage
CBIO's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
CBIO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.5 | Neutral |
| Stochastic | 19.1 | Oversold |
CBIO's weekly RSI is 46 (neutral) and its Stochastic is 19 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
CBIO PE vs Healthcare Sector
CBIO has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
CBIO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.7 | 5.2% above |
| 20 week MA | $15.8 | 8.8% below |
| 50 week MA | $15.4 | 6.7% below |
| 100 week MA | $17.3 | 17% below |
| 200 week MA | $80.5 | 82% below |
CBIO has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
CBIO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $570.0 | $412.0 | -28% |
| 2021 | $412.0 | $160.0 | -61% |
| 2022 | $160.0 | $227.0 | +42% |
| 2023 | $227.0 | $236.0 | +4% |
| 2024 | $236.0 | $23.6 | -90% |
| 2025 | $23.6 | $12.4 | -48% |
| 2026 YTD | $12.4 | $14.4 | +16% |
CBIO has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.